The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
|
|---|---|
| Published in |
Blood Cancer Discovery, April 2023
|
| DOI | 10.1158/2643-3230.bcd-22-0205 |
| Pubmed ID | |
| Authors |
Curtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R Luskin, Dzifa Y Duose, Rebecca S S Tidwell, Nicholas J Short, Gautam Borthakur, Tapan M Kadia, Lucia Masarova, George D Tippett, Prithviraj Bose, Elias J Jabbour, Farhad Ravandi, Naval G Daver, Guillermo Garcia-Manero, Hagop Kantarjian, Jacqueline S Garcia, Paresh Vyas, Koichi Takahashi, Marina Konopleva, Courtney D DiNardo |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 20% |
| India | 1 | 2% |
| United Kingdom | 1 | 2% |
| Unknown | 35 | 76% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 57% |
| Scientists | 11 | 24% |
| Practitioners (doctors, other healthcare professionals) | 7 | 15% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 12% |
| Unspecified | 2 | 8% |
| Other | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Researcher | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 13 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Unspecified | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Immunology and Microbiology | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 15 | 58% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2024.
All research outputs
#794,007
of 26,289,377 outputs
Outputs from Blood Cancer Discovery
#36
of 222 outputs
Outputs of similar age
#17,088
of 419,601 outputs
Outputs of similar age from Blood Cancer Discovery
#6
of 12 outputs
Altmetric has tracked 26,289,377 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 222 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,601 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.